iiCON bridges the gap in the infection innovation ecosystem between industry, academia, and the NHS, to accelerate and support the discovery and development of innovative new anti-infectives, diagnostics, and preventative products.
Learn moreEstablished in 2020, iiCON brings together industry, academia, and the NHS in a concerted effort with a clear aim: to save lives globally by accelerating the discovery and development of new treatments, diagnostics, vaccines, and preventative products for infectious diseases.
Based within the North West of England and led by Liverpool School of Tropical Medicine, iiCON’s partners are Unilever, LifeArc, Liverpool University Hospitals Foundation Trust, University of Liverpool, Evotec, and Infex Therapeutics.
The consortium works with companies of all sizes, supporting them at all stages of the innovation journey, from product concept to adoption.
iiCON does this by enabling impactful collaborations and providing companies with access to world leading expertise and facilities across eleven specialist research platforms co-developed and operated by its industrial, academic, and clinical partners.
Our purpose is to drive excellence in infection innovation through collaboration, improving health outcomes and creating social value in communities locally and globally.
We aim to save and improve the lives of millions of people by accelerating the product discovery and development journey.
Our work brings new drugs, diagnostics, vaccines and products to patients and communities more quickly, safely, and affordably – helping to ease the global burden of infectious disease.